JenaValve today announced new results from an expanded cohort receiving its Trilogy transcatheter heart valve (THV) system.

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

device developed specifically for the treatment for aortic regurgitation has met all the prespecified safety and efficacy goals, so far, in an expansion cohort of the ALIGN-AR trial, paving the ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial’s ...